Evidence map›Paper›PMID 38962492›Full record

ArticleJournal of biomedical optics2024

Multispectral label-free

Karteek Kunala, Janet A H Tang, Keith Parkins, Jennifer J Hunter

Abstract read
In one paragraph

Article in Journal of biomedical optics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Karteek KunalaStanford University, Byers Eye Institute, Palo Alto, California, United States.
Janet A H TangUniversity of Rochester, Center for Visual Science, Rochester, New York, United States.
Keith ParkinsUniversity of Rochester, Center for Visual Science, Rochester, New York, United States.ORCID 0000-0001-8987-6954
Jennifer J HunterUniversity of Rochester, Center for Visual Science, Rochester, New York, United States.

Funding

VISUAL SCIENCE RESEARCH CTR SUPPORTP30EY001319 · NEI · UNIVERSITY OF ROCHESTER · PI MICHELE RUCCI · 1985 to 2026
$17.5M
Adaptive Optics Fluorescence Lifetime Ophthalmoscopy (AOFLIO) in healthy people and with diseaseR01EY032116 · NEI · UNIVERSITY OF WATERLOO · PI Jennifer J Hunter · 2021 to 2026
$1.4M
NEI NIH HHS P30 EY001319NEI NIH HHS R01 EY032116
6 · The paper itself

Abstract

Significance: Adaptive optics fluorescence lifetime ophthalmoscopy (AOFLIO) provides a label-free approach to observe functional and molecular changes at cellular scale Aim: To quantify the cellular-scale changes in autofluorescence with age and eccentricity due to variations in lipofuscin, melanin, and melanolipofuscin in RPE using multispectral AOFLIO. Approach: AOFLIO was performed on six subjects at seven eccentricities. Four imaging channels ( Results: A repeatability analysis revealed Conclusions: Multispectral AOFLIO can provide a more comprehensive picture of changes with age and eccentricity. These results indicate that cell segmentation has the potential to allow investigations in low-photon scenarios such as in older or diseased subjects with the co-capture of an NIR channel (such as 765/NIR) with the desired spectral channel. This work represents the first multispectral, cellular-scale fluorescence lifetime comparison

Indexed as

OphthalmoscopyRetinal Pigment EpitheliumAdultAgedAgingFeasibility StudiesFemaleHumansLipofuscinMaleMiddle AgedOptical ImagingYoung AdultLipofuscinadaptive opticsfluorescence lifetime imagingin vivo imaginglipofuscin and melaninmultispectral imagingretinal pigment epithelium

Identifiers

PMID38962492
PMCPMC11221116

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.